Jia Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre , shared on LinkedIn:
“And Professor Jayesh Desai from Peter MacCallum Cancer Centre discussing dose escalation trials and whether they are fit for purpose for ADC drug development – need for collaboration to ensure we enrol the right patients on the right trials, toxicity assessment given narrow therapeutic index and emergence of screening multiplex IHCs needed.”
More posts featuring Jia (Jenny) Liu.
